Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROLONG: HPC for Preterm Birth Prevention
NCT01004029Phase 3Completed
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Oct 2009
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of hydroxyprogesterone caproate in preterm birth, sponsored by AMAG Pharmaceuticals, Inc.. Started Oct 2009; status: completed.
02
Drugs
hydroxyprogesterone caproate
03
Conditions
preterm birth
Beyond the preview
Go deeper on NCT01004029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01004029.